Inovio Pharmaceuticals (NASDAQ:INO) was first formed way back in 1983. After 33 years and several name changes, the company still doesn’t have a product on the market. Inovio does have several pipeline candidates that could eventually become winners. Here’s why the biotech’s best chance for success might come from a DNA vaccine that’s still in early-stage testing: INO-3112.
